Maze Therapeutics, Inc. (MAZE) has received a new Buy rating, initiated by J.P. Morgan analyst, Anupam Rama.
Anupam Rama has given his Buy rating due to a combination of factors that highlight the potential of Maze Therapeutics, Inc. The company’s lead asset, MZE829, an APOL1 inhibitor for APOL1 kidney disease, is currently in a phase 2 study, with promising initial data expected in the first quarter of 2026. This asset is seen as a key driver for the company’s shares, with multiple factors such as the breadth of the addressable population, pricing, and market share contributing to its potential success.
Anupam Rama also notes the potential of Maze’s proprietary COMPASS platform, which has produced other promising programs like MZE782 and MZE001. While these are in earlier stages and not core value drivers in the near term, they validate the company’s innovative approach. The valuation model includes MZE829 with an assumed peak worldwide sales of approximately $2 billion, contributing significantly to the December 2025 price target of $30. Overall, the combination of MZE829’s potential and the broader pipeline supports the Buy rating.
Rama covers the Healthcare sector, focusing on stocks such as Neurocrine, Oric Pharmaceuticals, and Olema Pharmaceuticals. According to TipRanks, Rama has an average return of 0.5% and a 41.62% success rate on recommended stocks.
In another report released today, Guggenheim also initiated coverage with a Buy rating on the stock with a $19.00 price target.